$ILMN (Illumina Inc.)

$ILMN {{ '2016-07-26T21:45:06+0000' | timeago}} • Webcast

$ILMN said that it is making good progress in the action plan which it put into practice after 1Q16. During 2Q16, the company improved sales processes and slowed down its pace of hiring, discretionary travel, and other external spends​. $ILMN added that its manufacturing and supply chain execution also improved.

$ILMN {{ '2018-01-16T12:42:12+0000' | timeago}} • Announcement

Luna DNA, the first and only genomic and medical research knowledge base powered by the blockchain and owned by its community, appointed Dawn Barry as president. Previously, Barry served as the VP of Applied Genomics at $ILMN.

$TMO {{ '2018-01-09T12:43:22+0000' | timeago}} • Announcement

$TMO, a leading medical technology company, has signed an agreement with life sciences firm $ILMN, under which Thermo Fisher will provide Illumina with Ion AmpliSeq technology. The tie-up will help Illumina effectively sell Ion AmpliSeq technology to researchers engaged in scientific studies on its next-generation sequencing (NGS) platforms.

$ILMN {{ '2017-12-11T15:09:10+0000' | timeago}} • Announcement

$ILMN said Aimee Hoyt will head its human resources team. Hoyt will join as SVP and Chief People Officer (CPO), starting Jan. 8, 2018, and will be responsible for leading all aspects of the company’s HR strategies, reporting to CEO Francis deSouza.

$DIS {{ '2017-12-08T11:53:58+0000' | timeago}} • Announcement

$DIS' BoD elected two new directors: Safra Catz, CEO of global-technology leader $ORCL, and Francis deSouza, President and CEO of biotechnology firm $ILMN. The elections of Catz and deSouza are effective Feb. 1, 2018.

$ILMN {{ '2017-10-24T21:53:31+0000' | timeago}} • Announcement

$ILMN shares rise nearly 1.2% after the gene sequencing company reported a 13% growth in its profit for the third quarter of 2017. With the launch of Helix’s first online marketplace for DNA-powered products a few weeks back, $ILMN’s OpEx sees an increase of 14% in the third quarter of 2017 to $301MM.

$ILMN {{ '2017-10-24T20:30:54+0000' | timeago}} • Infographic

$ILMN Illumina, Inc. Earnings AlphaGraphic: Q3 2017 Highlights

$ILMN {{ '2017-09-07T17:16:59+0000' | timeago}} • Announcement

$ILMN filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in UK. $ILMN is seeking all available remedies, including damages and injunctive relief. The suit accuses Premaitha's IONA Test of infringing European Patent titled, "Non-invasive Detection of Fetal Genetic Traits."

$ILMN {{ '2017-08-24T14:30:17+0000' | timeago}} • Announcement

$ILMN and Telegraph Hill Partners launched Verogen Inc. Verogen is headquartered in San Diego. It will be the sole provider of the MiSeq FGx Forensic Genomics System, including the MiSeq FGx sequencer, and has global commercial rights to these products. Kirk Malloy will be CEO of Verogen and Cydne Holt will be GM & Chief Scientific Officer.

$ILMN {{ '2017-08-24T14:30:00+0000' | timeago}} • Announcement

$ILMN announced plans with Telegraph Hill Partners, a San Francisco-based venture capital firm, to establish Verogen, Inc. The independent new company has certain exclusive rights to provide $ILMN’s forensic sequencing technology to forensic customers, including for criminal casework and other forensic applications.

$ILMN {{ '2017-08-01T21:54:49+0000' | timeago}} • Infographic

$ILMN Illumina, Inc. AlphaGraphic: Q2 2017 Highlights

$ILMN {{ '2017-05-22T15:06:11+0000' | timeago}} • Announcement

$ILMN appointed Mark Van Oene as Chief Commercial Officer. Van Oene was previously $ILMN's SVP of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. As Chief Commercial Officer, Van Oene will be responsible for world-wide sales, services and marketing at $ILMN. He will report to CEO Francis deSouza.

$ILMN {{ '2017-04-25T22:27:16+0000' | timeago}} • Webcast

$ILMN expects gross margin to be slightly lower in 2Q17 compared to 1Q17. The operating expense growth also is expected to the drive EPS. The company said that it is seeing new customers emerging in China and it remains bullish on the Chinese market opportunities.

$ILMN {{ '2017-04-25T20:37:01+0000' | timeago}} • Announcement

For 2Q17, $ILMN  expects revenue growth of approx. 7% versus a year ago. GAAP earnings per diluted share attributable to company stockholders is expected to be $0.56-0.61 and non-GAAP earnings per diluted share attributable to company stockholders is expected in the range of $0.65-0.70 for 2Q17.

$ILMN {{ '2017-04-25T20:36:13+0000' | timeago}} • Announcement

For FY17, $ILMN expects revenue growth in the range of 10-12%. Additionally, GAAP diluted EPS attributable to company stockholders is expected to be $5.26-5.36 and non-GAAP EPS attributable to company stockholders is expected to be $3.60-3.70 for FY17.

$ILMN {{ '2017-04-25T20:30:02+0000' | timeago}} • Announcement

Life science research company $ILMN's earnings for 1Q17 quadrupled, helped by a pre-tax gain of $453MM resulting from the GRAIL repurchase of shares from $ILMN. Net income jumped 314% to $373MM or $2.52 per share from $90MM or $0.60 per share a year ago. Revenue increased 4.54% to $598MM.

$ILMN {{ '2017-01-31T23:23:11+0000' | timeago}} • Webcast

$ILMN said that Asia Pacific had a significant growth in 4Q16 as revenue increased 29% YoverY, propelled by China which grew approx. 50%. Europe grew 11%, driven in part by year-end spending. Americas revenue declined 4% due to lower high throughput sequencing instrument shipments.

$ILMN {{ '2017-01-31T23:18:17+0000' | timeago}} • Webcast

$ILMN ended 2016 with approx. 35 HiSeq X customers and 37 HiSeq X instruments and backlogs, which are candidates for conversation to NovaSeq.

$ILMN {{ '2017-01-31T21:59:15+0000' | timeago}} • Announcement

For 1Q17, $ILMN expects revenue to be $580-595MM, GAAP diluted EPS attributable to company stockholders to be $0.51-0.56 and non-GAAP diluted EPS attributable to company stockholders to be $0.60-0.65.

$ILMN {{ '2017-01-31T21:58:45+0000' | timeago}} • Announcement

For FY17, $ILMN projects revenue to grow 10-12%, GAAP diluted EPS attributable to company stockholders to be $3.25-3.35 and non-GAAP diluted EPS attributable to company stockholders to be $3.60-3.70.

$ILMN {{ '2017-01-31T21:54:49+0000' | timeago}} • Announcement

$ILMN reported a rise in 4Q16 profit, helped by higher revenues. Net income rose 18.5% YoY to $123.8MM or $0.84 per diluted share. Revenue increased 5% to $619MM. Non-GAAP EPS was $0.85 compared to $0.81 in the prior year quarter.

Recent Transcripts

A (Agilent Technologies Inc.)
Monday, November 20 2017 - 9:30pm
AIRI (Air Industries Group)
Thursday, November 16 2017 - 1:30pm
COHR (Coherent Inc.)
Tuesday, November 7 2017 - 9:30pm
PSDV (pSivida Corp.)
Tuesday, November 7 2017 - 1:30pm
FLDM (Fluidigm Corporation)
Thursday, November 2 2017 - 9:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
PKI (PerkinElmer Inc.)
Thursday, November 2 2017 - 9:00pm
PACB (Pacific Biosciences of California, Inc.)
Thursday, November 2 2017 - 8:30pm
GNMK (GenMark Diagnostics, Inc.)
Thursday, November 2 2017 - 8:30pm
QDEL (Quidel Corp.)
Wednesday, November 1 2017 - 9:00pm
LBY (Libbey Inc.)
Tuesday, October 31 2017 - 3:00pm
SNE (Sony Corporation)
Tuesday, October 31 2017 - 7:30am
GOOGL (Alphabet Inc.)
Thursday, October 26 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
F (Ford Motor Co.)
Thursday, October 26 2017 - 1:00pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, October 25 2017 - 12:30pm
ILMN (Illumina Inc.)
Tuesday, October 24 2017 - 9:00pm

AlphaGraphics you may like